A European perspective on Health Resource Utilization (HRU) and Cost outcomes in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review

Author(s)

Maria victoria Mateos, MD1, Ken Hasegawa, PhD2, Taha Itani, PhD, MPH2, Monique Giordana, PharmD, BCOP2, Enrique Granados, MD2, Jie Ting, MSPH, PhD3, Rebecca J Chan, MD, PhD3, Ana Kostic, MD3, Noor-E Zannat, MA (Econ)4, Pardis Lakzadeh, MSc4, Doris K. Hansen, MD5;
1University Hospital of Salamanca/IBSAL, Salamanca, Spain, 2Kite, A Gilead Company, Santa Monica, CA, USA, 3Arcellx, Inc., Redwood City, CA, USA, 4RainCity Analytics, Vancouver, BC, Canada, 5H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
OBJECTIVES: As RRMM rates increase, so does the related economic burden. Given the dynamic RRMM treatment landscape, understanding current HRU and cost patterns helps inform the potential impact of novel therapies. We have previously described the RRMM-related HRU and cost in the US. This study will focus on these outcomes among RRMM patients in Europe
METHODS: MEDLINE, Embase, EconLit, and NHS-EED were systematically searched from January 2012-March 2024 to identify observational studies and trials (hospitalization-related outcomes only) describing the economic burden of RRMM. Relevant conference proceedings were also reviewed for this period. Costs were adjusted to 2024 EUR.
RESULTS: Searches identified 5,372 citations with 22 eligible records (18 unique studies) describing HRU or cost outcomes in Europe. Four studies described the total cost of care by components. Medications (48-93% of total costs, n=4 studies) were the primary cost driver, followed by hospitalizations (5-25% of total costs, n=4 studies). In a within-study comparison of costs between three European countries, the mean total cost for one line of therapy (LOT) was highest in the UK (€65,069) followed by France (€46,564) and Italy (€43,402). In all three regions, anti-myeloma medications accounted for 90-95% of total costs. While HRU reporting was inconsistent, a significant proportion of patients across regions required visits to general practitioners, outpatient visits, or hospitalizations. Within-study comparisons revealed increases in hospitalization rates across LOT, with the highest rates observed during active treatment. Specifically, in the 5L+ setting, 64%, 73%, and 50% of patients experienced at least one hospitalization during active treatment in the UK, France and Italy, respectively.
CONCLUSIONS: Managing RRMM patients is resource-intensive and costly, with medications identified as the primary cost driver across Europe. Managing these costs requires new treatments to prevent or delay initiation of subsequent LOT, thereby minimizing prolonged HRU and costs, particularly in the more costly later stages of treatment.

Conference/Value in Health Info

2025-05, ISPOR 2025, Montréal, Quebec, CA

Value in Health, Volume 28, Issue S1

Code

EE371

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

SDC: Oncology

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×